​

Lucid Diagnostics (LUCD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LUCD Stock Forecast

Lucid Diagnostics (LUCD) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $2.50, with a high of $3.00 and a low of $2.00. This represents a 98.41% increase from the last price of $1.26.

High: $3 Avg: $2.5 Low: $2 Last Closed Price: $1.26

LUCD Stock Rating

Lucid Diagnostics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

LUCD Price Target Upside V Benchmarks

TypeNameUpside
StockLucid Diagnostics98.41%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks18.84%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$2.25
Last Closing Price$1.26$1.26$1.26
Upside/Downside--78.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2524---6
Sep, 2524---6
Aug, 2524---6
Jul, 2524---6
Jun, 2524---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 25, 2025BTIG$2.00$1.5529.03%58.73%
Nov 13, 2024Mike MatsonNeedham$2.50$0.79216.46%98.41%
May 14, 2024Kyle MiksonCanaccord Genuity$3.00$0.95215.79%138.10%
Apr 08, 2024Mark MassaroBTIG$2.50$0.93168.82%98.41%
Nov 18, 2022BTIG$3.50$1.9183.25%177.78%
Nov 15, 2022Needham$3.10$2.2736.56%146.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 05, 2025BTIGBuyBuyhold
Nov 13, 2024NeedhamBuyBuyhold
Oct 14, 2024BTIGBuyBuyhold
Apr 08, 2024BTIGBuyBuyhold
Nov 18, 2022BTIGBuyBuyhold
Nov 15, 2022NeedhamBuyBuyhold
Apr 26, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-2K $-1K $-900 $-600 $-300 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.82$-1.55$-1.26$-1.05K----
Avg Forecast$-1.21$-1.22$-0.92$-0.89$-0.62$-0.41$-0.47$-0.39
High Forecast$-0.81$-0.97$-0.71$-0.68$-0.47$-0.18$-0.36$-0.30
Low Forecast$-2.22$-1.48$-1.15$-1.11$-0.77$-0.62$-0.59$-0.49
Surprise %-32.23%27.05%36.96%117840.45%----

Revenue Forecast

$0 $900M $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$500.00K$377.00K$2.43M$4.35B----
Avg Forecast$500.00K$577.16K$2.43M$4.56M$10.92M$33.51M$33.30M$50.40M
High Forecast$816.71K$673.83K$2.68M$5.43M$13.01M$33.53M$39.64M$60.00M
Low Forecast$372.17K$487.29K$2.28M$3.75M$8.97M$33.49M$27.34M$41.37M
Surprise %--34.68%-95137.18%----

Net Income Forecast

$-55B $-44B $-33B $-22B $-11B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.74M$-56.17M$-52.67M$-53.02B----
Avg Forecast$-50.72M$-50.84M$-38.70M$-37.44M$-25.87M$-16.68M$-19.77M$-16.28M
High Forecast$-33.86M$-40.55M$-29.47M$-28.51M$-19.70M$-7.46M$-15.06M$-12.49M
Low Forecast$-92.49M$-61.91M$-47.93M$-46.36M$-32.04M$-25.90M$-24.48M$-20.32M
Surprise %-43.35%10.49%36.09%141535.26%----

LUCD Forecast FAQ

Is Lucid Diagnostics stock a buy?

Lucid Diagnostics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Lucid Diagnostics is a favorable investment for most analysts.

What is Lucid Diagnostics's price target?

Lucid Diagnostics's price target, set by 5 Wall Street analysts, averages $2.5 over the next 12 months. The price target range spans from $2 at the low end to $3 at the high end, suggesting a potential 98.41% change from the previous closing price of $1.26.

How does Lucid Diagnostics stock forecast compare to its benchmarks?

Lucid Diagnostics's stock forecast shows a 98.41% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (18.84%).

What is the breakdown of analyst ratings for Lucid Diagnostics over the past three months?

  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Lucid Diagnostics’s EPS forecast?

Lucid Diagnostics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a -99.94% decrease from the reported $-1.05K in 2024. Estimates for the following years are $-0.41 in 2026, $-0.47 in 2027, and $-0.39 in 2028.

What is Lucid Diagnostics’s revenue forecast?

Lucid Diagnostics's average annual revenue forecast for its fiscal year ending in December 2025 is $10.92M, reflecting a -99.75% decrease from the reported $4.35B in 2024. The forecast for 2026 is $33.51M, followed by $33.3M for 2027, and $50.4M for 2028.

What is Lucid Diagnostics’s net income forecast?

Lucid Diagnostics's net income forecast for the fiscal year ending in December 2025 stands at $-25.87M, representing a -99.95% decrease from the reported $-53.025B in 2024. Projections indicate $-16.678M in 2026, $-19.77M in 2027, and $-16.285M in 2028.